The preoperative machine learning algorithm for extremity metastatic disease can predict 90-day and 1-year survival: An external validation study

16Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: The prediction of survival is valuable to optimize treatment of metastatic long-bone disease. The Skeletal Oncology Research Group (SORG) machine-learning (ML) algorithm has been previously developed and internally validated. The purpose of this study was to determine if the SORG ML algorithm accurately predicts 90-day and 1-year survival in an external metastatic long-bone disease patient cohort. Methods: A retrospective review of 264 patients who underwent surgery for long-bone metastases between 2003 and 2019 was performed. Variables used in the stochastic gradient boosting SORG algorithm were age, sex, primary tumor type, visceral/brain metastases, systemic therapy, and 10 preoperative laboratory values. Model performance was calculated by discrimination, calibration, and overall performance. Results: The SORG ML algorithms retained good discriminative ability (area under the cure [AUC]: 0.83; 95% confidence interval [CI]: 0.76–0.88 for 90-day mortality and AUC: 0.84; 95% CI: 0.79–0.88 for 1-year mortality), calibration, overall performance, and decision curve analysis. Conclusion: The previously developed ML algorithms demonstrated good performance in the current study, thereby providing external validation. The models were incorporated into an accessible application (https://sorg-apps.shinyapps.io/extremitymetssurvival/) that may be freely utilized by clinicians in helping predict survival for individual patients and assist in informative decision-making discussion before operative management of long bone metastatic lesions.

Cite

CITATION STYLE

APA

Skalitzky, M. K., Gulbrandsen, T. R., Groot, O. Q., Karhade, A. V., Verlaan, J. J., Schwab, J. H., & Miller, B. J. (2022). The preoperative machine learning algorithm for extremity metastatic disease can predict 90-day and 1-year survival: An external validation study. Journal of Surgical Oncology, 125(2), 282–289. https://doi.org/10.1002/jso.26708

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free